Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China

Diagnostic Microbiology and Infectious Disease

Volumn 77, Issue 2, 2013, Pages 138-142

  Du, Qinglin ^a   Dai, Guangming ^b   Long, Quanxin ^a   Yu, Xia ^b   Dong, Lingling ^b   Huang, Hairong ^b   Xie, Jianping ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Amikacin; Capreomycin; Kanamycin; Mycobacterium tuberculosis; Rrs A1401G

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN;

5' UNTRANSLATED REGION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; CHINA; CONTROLLED STUDY; CORRELATION ANALYSIS; EIS GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RRS GENE; TLYA GENE; WHIB7 GENE;

AMIKACIN; CAPREOMYCIN; KANAMYCIN; MYCOBACTERIUM TUBERCULOSIS; RRS A1401G;

AMIKACIN; ANTITUBERCULAR AGENTS; CAPREOMYCIN; CHINA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, BACTERIAL; HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84884415938     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.06.031     Document Type: Article

References (28)

1. Alangaden G.J., Kreiswirth B.N., Aouad A., Khetarpal M., Igno F.R., Moghazeh S.L., et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:1295-1297.
2. Aldous W.K., Pounder J.I., Cloud J.L., Woods G.L. Comparison of six methods of extracting Mycobacterium tuberculosis DNA from processed sputum for testing by quantitative real-time PCR. J Clin Microbiol 2005, 43:2471-2473.
3. Campbell P.J., Morlock G.P., Sikes R.D., Dalton T.L., Metchock B., Starks A.M., et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, 55:2032-2041.
4. Chan E.D., Strand M.J., Iseman M.D. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin Infect Dis 2009, 48:e50-e52.
5. Chen W., Biswas T., Porter V.R., Tsodikov O.V., Garneau-Tsodikova S. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. Proc Natl Acad Sci U S A 2011, 108:9804-9808.
6. Collins L., Franzblau S.G. Microplate Alamar Blue Assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997, 41:1004-1009.
7. Engstrom A., Perskvist N., Werngren J., Hoffner S.E., Jureen P. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2011, 66:1247-1254.
8. Falzon D., Jaramillo E., Schunemann H.J., Arentz M., Bauer M., Bayona J., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
9. Feuerriegel S., Cox H.S., Zarkua N., Karimovich H.A., Braker K., Rusch-Gerdes S., et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009, 53:3353-3356.
10. Franzblau S.G., Witzig R.S., McLaughlin J.C., Torres P., Madico G., Hernandez A., et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the Microplate Alamar Blue Assay. J Clin Microbiol 1998, 36:362-366.
11. Georghiou S.B., Magana M., Garfein R.S., Catanzaro D.G., Catanzaro A., Rodwell T.C. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012, 7:e33275.
12. Houghton J.L., Green K.D., Pricer R.E., Mayhoub A.S., Garneau-Tsodikova S. Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes. J Antimicrob Chemother 2013, 68:800-805.
13. Johansen S.K., Maus C.E., Plikaytis B.B., Douthwaite S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. Mol Cell 2006, 23:173-182.
14. Jugheli L., Bzekalava N., de Rijk P., Fissette K., Portaels F., Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009, 53:5064-5068.
15. Kruuner A., Jureen P., Levina K., Ghebremichael S., Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:2971-2973.
16. Maus C.E., Plikaytis B.B., Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:3192-3197.
17. Maus C.E., Plikaytis B.B., Shinnick T.M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:571-577.
18. Perdigao J., Macedo R., Malaquias A., Ferreira A., Brum L., Portugal I. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010, 65:224-227.
19. Reeves A.Z., Campbell P.J., Sultana R., Malik S., Murray M., Plikaytis B.B., et al. Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5' untranslated region of whiB7. Antimicrob Agents Chemother 2013, 57:1857-1865.
20. Russell D.G., Barry C.E., Flynn J.L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328:852-856.
21. Shah N.S., Wright A., Bai G.H., Barrera L., Boulahbal F., Martin-Casabona N., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007, 13:380-387.
22. Sirgel F.A., Tait M., Warren R.M., Streicher E.M., Bottger E.C., Van Helden P.D., et al. Mutations in the rrs A1401G gene and phenotypic resistance to Amikacin and Capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 2012, 18:193-197.
23. Springer B., Lucke K., Calligaris-Maibach R., Ritter C., Bottger E.C. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009, 47:1773-1780.
24. Suzuki Y., Katsukawa C., Tamaru A., Abe C., Makino M., Mizuguchi Y., et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998, 36:1220-1225.
25. Taniguchi H., Chang B., Abe C., Nikaido Y., Mizuguchi Y., Yoshida S.I. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 1997, 179:4795-4801.
26. Via L.E., Cho S.N., Hwang S., Bang H., Park S.K., Kang H.S., et al. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol 2010, 48:402-411.
27. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line anti-tuberculosis drugs. Report (WHO/HTM/TB/2008392) 2008, 1-20.
28. Zaunbrecher M.A., Sikes R.D., Metchock B., Shinnick T.M., Posey J.E. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2009, 106:20004-20009.